The liposarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage liposarcoma drugs, inactive and dormant assets, a comprehensive ...

Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin ...

In further tests, the method was applied to proteins with essential cellular functions, including the transcription factor c-Myc and the kinase Chk1. Specific protein segments were temporarily ...

Kunz, MD. † Plain Language Summary written by JCO Oncology Advances Associate Editor Mark Lewis, MD. Checkpoint kinase proteins 1 (CHK1) and 2 (CHK2) are conserved serine/threonine kinases and are key ...

Real-World Utilization and Performance of Circulating Tumor DNA Monitoring to Predict Recurrence in Solid Tumors Preclinical data confirmed ACR-368 as potentially therapeutic in DSRCT, and 19 patients ...

The Watertown, Massachusetts-based biotech had been evaluating the CHK1/2 inhibitor, called prexasertib or ACR-368, in a phase 2b trial of patients with endometrial cancer. These patients were ...

Cells respond to this conflict by the heavy use of a protein called CHK1, which helps fix DNA and allows the cell to keep growing. When the researchers used a drug called BBI-2779 that blocks CHK1 ...

CHK1 mutations could cause human zygote arrest at the pronuclei stage, a phenomenon that is not well understood at the molecular level. In this study, we conducted experiments where pre-pronuclei from ...

Furthermore these sameconditions target Chk1 for eventual destruction. Ironically,stimulation of Chk1 triggers certain repair responses that fight cancerwhile the simultaneous degradation of Chk1 ...

The S-phase checkpoint involving CHK1 is essential for fork stability in response to fork stalling. PARP1 acts as a sensor of replication stress and is required for CHK1 activation. However, it is ...